A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
- 28 Aug 2015 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018 as reported by ClinicalTrials.gov.
- 05 May 2014 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.